Previous 10 | Next 10 |
Some major changes in my portfolio in March including an entrance back into a few China stocks, some new Healthcare picks, and a new large financial SPAC position. I also sold off some of my more defensive value positions during the last rotation to add to some of my key tech position...
MiMedx Group (MDXG) has been awarded a group purchasing agreement by Premier Inc. under the latter’s SURPASS (Synergizing for Unparalleled Results in Procurement and Strategic Sourcing) purchasing program.With effect from April 01, 2021, SURPASS members can benefit from speci...
MARIETTA, Ga., March 30, 2021 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MiMedx” or the “Company”), an industry leader in utilizing birth tissue as a platform for regenerative medicine, today announced that the Company has been awarded a Group Purcha...
The following slide deck was published by MiMedx Group, Inc. in conjunction with this event. For further details see: MiMedx Group (MDXG) Presents At H.C. Wainwright Global Life Sciences Virtual Conference - Slideshow
FDA scare for $20M-25M a year does not change the long-term profit narrative for MiMedx. Upcoming KOA data could justify $4.5B-9.0B in peak potential annual sales. Lottery ticket unloved biotech could justify a 10X return over the coming years, and I'm buying shares hand over fist...
MiMedx Group, Inc. (MDXG) Q4 2020 Earnings Conference Call March 08, 2021, 09:30 AM ET Company Participants Jack Howarth - VP of IR and Corporate Communications Tim Wright - CEO Pete Carlson - CFO Robert Stein - EVP, Research & Development Rohit Kashyap - EVP and Chief Commercial Officer ...
MiMedx Group (MDXG): Q4 GAAP EPS of -$0.17 misses by $0.12.Adj. Revenue of $68.02M (-0.2% Y/Y) beats by $6.02M.Adjusted EBITDA of $10.3 million for the fourth quarter and $30.6 million for the full year.Press Release For further details see: MiMedx Group EPS misses by $0.12, beats ...
Noted biopharmaceutical thought leader adds academic, research and industry expertise MARIETTA, Ga., March 08, 2021 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MiMedx” or the “Company”), an industry leader in utilizing birth tissue as a plat...
Fourth Quarter Net Sales of $68.5 million, Full Year 2020 Net Sales of $248.2 million Company to Host Conference Call on March 9, 2021 at 9:30 AM ET MARIETTA, Ga., March 08, 2021 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MiMedx” or the “C...
MARIETTA, Ga., March 03, 2021 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MiMedx” or the “Company”), an industry leader in advanced wound care and a therapeutic biologics company, today announced that management will be participating in the following ...
News, Short Squeeze, Breakout and More Instantly...
Study adds to the Company’s growing body of evidence and expands the understanding of the regulatory capabilities of its DHACM and LHACM allografts on the fibrotic process Marks MIMEDX’s first publication in the 5 th most-cited journal in the world MARIET...
Rick Barry appointed Executive Chairman of the Board Remi Barbier resigns as President and CEO and from the Board of Directors Cassava initiates search for a new CEO AUSTIN, Texas, July 17, 2024 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA) today announced that the Boa...
MARIETTA, Ga., July 17, 2024 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”) today announced that it will report its operating and financial results for the second quarter ended June 30, 2024 after the market close on Wednesday, July 3...